This narrative review assesses the safety, effectiveness and efficiency of the BNT162b2 (Pfizer) vaccination across diverse demographics, including age groups, geographical locations, communities, genders, and ethnicities. It specifically examines the vaccine’s impact on elderly individuals and pregnant women, focusing on its effectiveness over six months.
Incorporating findings from five research papers, the review considers design-related aspects and reports on vaccination effectiveness in preventing RT-PCR-confirmed COVID-19. Exclusion criteria eliminate studies with non-specific outcomes, individuals with a history of COVID-19, and those on immunosuppressive therapy. The study does not delve into vaccine efficacy against specific SARS-CoV-2 variants, emphasizing a primary interest in the reduction of RT-PCR-verified COVID-19 in vaccinated versus unvaccinated individuals.
The BNT162b2 vaccine is deemed safe and highly effective, demonstrating 95% efficacy in those 16 and above, and 100% in 12 to 15-year-olds. Minimal adverse events, lasting one to two days, are reported. The vaccine's safety extends to older and pregnant individuals. However, a noteworthy finding reveals a 6% decline in efficacy every two months during follow-up, indicating a time-limited effectiveness.
In conclusion, the narrative review highlights the BNT162b2 vaccine's overall
safety and high efficacy across diverse populations. While showing effectiveness over six
months, the observed decline in efficacy emphasizes a temporal limitation, necessitating
ongoing research and monitoring to optimize vaccination strategies and address challenges
tied to waning effectiveness.
